From: Pharmacotherapy and the risk for community-acquired pneumonia
Variables* N (%) | Cases N = 194 | Control N = 952 | P value§ |
---|---|---|---|
Mean age (yr) (SD) | 80.3 (8.5) | 79.8 (8.1) | .486 |
Female | 119 (61) | 641 (67) | .108 |
White | 194 (100) | 941 (98.8) | .133 |
Ex-smoker† | 60/191 (31) | 151/949 (16) | < .001 |
Current smoker† | 28/191 (15) | 73/949 (8) | .002 |
Past Medical History | |||
Congestive heart failure | 63 (32) | 201 (21) | < .001 |
Coronary artery disease | 77 (40) | 299 (31) | .025 |
COPD | 91 (47) | 178 (19) | < .001 |
Prior pneumonia | 38 (20) | 43 (5) | < .001 |
Diabetes mellitus | 52 (27) | 277 (29) | .520 |
Atrial fibrillation | 35 (18) | 136 (14) | .181 |
Stroke | 34 (18) | 148 (16) | .492 |
Cognitive impairment | 40 (21) | 152 (16) | .114 |
Depression | 58 (30) | 243 (26) | .207 |
Psychiatric illness | 7 (4) | 24 (3) | .395 |
GERD | 56 (29) | 233 (24) | .199 |
Medication | |||
Atypical antipsychotics | 25 (13) | 63 (7) | .003 |
Proton pump inhibitor | 86 (44) | 343 (36) | .030 |
H2 receptor antagonist | 7 (4) | 46 (5) | .460 |
Antihistamine | 29 (15) | 129 (14) | .607 |
β2 agonist bronchodilator | 72 (37) | 109 (11) | < .001 |
Inhaled corticosteroid | 49 (25) | 47 (5) | < .001 |
Anticholinergic bronchodilator | 44 (23) | 63 (7) | < .001 |
Antibiotic use prior to admission | 44 (23) | 88 (9) | < .001 |
NSAIDs | 27 (14) | 115 (12) | .479 |
Narcotics | 60 (31) | 224 (24) | .030 |
Iron supplement | 37 (19) | 82 (9) | < .001 |
Admission laboratory results | |||
Serum albumin (gm/dL) | 2.9 (0.5) (N = 167) | 3.2 (0.5) (N = 807) | < .001 |
White cell count (K/μL) | 13.6 (6.0) (N = 194) | 9.3 (4.0) (N = 949) | < .001 |
Serum potassium (mmol/L) | 4.1 (0.6) (N = 194) | 4.1 (0.7) (N = 948) | .631 |
Discharge diagnoses | |||
Congestive heart failure | 46 (24) | 107 (11) | < .001 |
Any GI-related illness | 18 (9) | 269 (28) | < .001 |
Upper GI illness‡ | 8 (4) | 100 (11) | .006 |
Lower GI illness¶ | 10 (5) | 140 (15) | < .001 |
C. difficile associated Diarrhea | 7 (4) | 27 (3) | .564 |